1. Home
  2. CXE vs RCEL Comparison

CXE vs RCEL Comparison

Compare CXE & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS High Income Municipal Trust

CXE

MFS High Income Municipal Trust

HOLD

Current Price

$3.71

Market Cap

118.1M

Sector

Finance

ML Signal

HOLD

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$3.42

Market Cap

102.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXE
RCEL
Founded
1989
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
118.1M
102.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CXE
RCEL
Price
$3.71
$3.42
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$8.67
AVG Volume (30 Days)
62.9K
197.9K
Earning Date
01-01-0001
02-12-2026
Dividend Yield
4.36%
N/A
EPS Growth
N/A
N/A
EPS
0.07
N/A
Revenue
N/A
$72,401,000.00
Revenue This Year
N/A
$13.12
Revenue Next Year
N/A
$27.56
P/E Ratio
$51.00
N/A
Revenue Growth
N/A
20.59
52 Week Low
$2.95
$3.25
52 Week High
$3.67
$14.16

Technical Indicators

Market Signals
Indicator
CXE
RCEL
Relative Strength Index (RSI) 52.10 41.28
Support Level $3.63 $3.36
Resistance Level $3.72 $3.61
Average True Range (ATR) 0.04 0.18
MACD 0.00 0.03
Stochastic Oscillator 67.23 34.78

Price Performance

Historical Comparison
CXE
RCEL

About CXE MFS High Income Municipal Trust

Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes.

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: